First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.

被引：0
|
作者：
Niho, S [1 ]
Kubota, K [1 ]
Goto, K [1 ]
Yoh, K [1 ]
Ohmatsu, H [1 ]
Kakinuma, R [1 ]
Nishiwaki, Y [1 ]
机构：
[1] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7059
引用
下载
收藏
页码：631S / 631S
页数：1
相关论文
共 50 条
  • [31] GEFITINIB AS FIRST-LINE THERAPY FOR ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS IN SOUTHERN TAIWAN
    Yang, Cheng-Ta
    Hung, Jen-Yu
    Lai, Chun-Liang
    Hung, Hsin-Chia
    Lai, Yung-Fa
    Lin, Meng-Chih
    Shieh, Jiunn-Min
    Huang, Ming-Shyang
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2010, 26 (01): : 1 - 7
  • [32] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
    Lee, Young Joo
    Kim, Heung Tae
    Han, Ji-Youn
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Sung, Ji-Hyun
    Lee, Jin Soo
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 361 - 368
  • [33] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [34] A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China
    Yang, Lu
    Wang, Zhi-jie
    An, Tong-tong
    Bai, Hua
    Zhao, Jun
    Duan, Jian-chun
    Li, Ping-ping
    Wu, Mei-na
    Sun, Hong
    Liang, Li
    Wang, Jie
    CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (01) : 1 - 9
  • [35] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Hyeong Su Kim
    Jung Han Kim
    Byounghoon Kim
    Hyun Chang Choi
    Jung Hye Kwon
    Dae Ro Choi
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1591 - 1597
  • [36] Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study
    Tartarone, A
    Romano, G
    Iodice, G
    Capobianco, A
    Coccaro, M
    Bochicchio, A
    Di Leo, P
    Ardito, R
    Di Renzo, N
    TUMORI, 2005, 91 (02) : 131 - 134
  • [37] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Byounghoon
    Choi, Hyun Chang
    Kwon, Jung Hye
    Choi, Dae Ro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1591 - 1597
  • [38] A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)
    Giorgio, CG
    Pappalardo, A
    Russo, A
    Giuffrida, D
    Santini, D
    Petralia, G
    Castorina, S
    Nunzio, R
    Failla, G
    Bordonaro, R
    LUNG CANCER, 2006, 51 (03) : 357 - 362
  • [39] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [40] Phase I-II study of irinotecan (CPT-11) and gefitinib in patients (pts) with gefitinib failure for non-small cell lung cancer (NSCLC)
    Horiike, A.
    Ohyanagi, F.
    Okano, Y.
    Kudo, K.
    Miyauchi, E.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345